Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice

Neurological Sciences

Volumn 34, Issue 4, 2013, Pages 521-528

  Lanzillo, R ^a,b   Bonavita, S ^c   Quarantelli, M ^a,d   Vacca, G ^a   Lus, G ^c   Amato, L ^a   Carotenuto, A ^a   Tedeschi, G ^b,c   Orefice, G ^a   Brescia Morra, V ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IDC Hermitage Capodimonte   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CNR   (Italy)

Author keywords

Annualised relapse rate; Longitudinal study; Multiple sclerosis; Natalizumab; Treatment failure

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; YOUNG ADULT;

EID: 84879686203     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-1088-8     Document Type: Article

References (21)

1. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
2. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933
3. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68(3):295-303
4. European Medicine Agency (2006) http://www.emea.europa.eu/humandocs/PDFs/ EPAR/tysabri/H-603-en6.pdf
5. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW et al (2006) Natalizumab plus interferon-β 1a for relapsing multiple sclerosis. N Engl J Med 354:911-923
6. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7):1277-1285
7. Klawiter EC, Cross AH, Naismith RT (2009) The present efficacy of multiple sclerosis therapeutics: is the new 66 % just the old 33 %? Neurology 73(12):984-990
8. Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V (2011) Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand. doi: 10.1111/j.1600-0404.2011.01622.x
9. Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C (2012) Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 18(1):64-71 PubMed PMID: 21828195
10. Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M et al (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(3):299-302
11. Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C (2011) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(Suppl 3):303-307
12. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA et al (2011) Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS ONE 6(2):e16664
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
15. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907-911
16. Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431-441
17. Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, Tur C, Comabella M,Montalban X (2012) Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. doi: 10.1111/j.1468-1331.2011.03648.x. (Epub ahead of print)
18. Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B (2010) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63(2):101-106
19. Outteryck O, Ongagna JC, Zéphir H, Fleury MC, Lacour A, Blanc F et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207-211
20. Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18(2):240-245
21. Oturai AB, Koch-Henriksen N, Petersen T et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16:420-423